SI-BONE, Inc. (NASDAQ:SIBN) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET

Company Participants

Saqib Iqbal - Director of Investor Relations

Laura Francis - Chief Executive Officer

Anshul Maheshwari - Chief Financial Officer

Conference Call Participants

Kyle Rose - Canaccord

David Rescott - Truist Securities

Craig Bijou - Bank of America

Ross Osborn - Cantor Fitzgerald

Dave Turkaly - JMP Securities

Drew Ranieri - Morgan Stanley

David Saxon - Needham & Company

Operator

Good afternoon, and welcome to SI-BONE's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Saqib Iqbal, Director of Investor Relations at SI-BONE’s [Indiscernible] introductory comments. Sir, you may begin.

Saqib Iqbal

Thank you for participating in today's call. Joining me are Laura Francis, Chief Executive Officer; and Anshul Maheshwari, Chief Financial Officer.

Earlier today, SI-BONE released financial results for the quarter ended December 31, 2022. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. These forward-looking statements are based on the company's current expectations and inherently involve risks and uncertainties. These risks include the duration of secondary impact of the COVID-19 pandemic such as facility staffing shortages, whether the COVID-19 pandemic will recur in the future and our ability to effectively commercialize new products going forward.

Other forward-looking statements include our examination of operating trends and our future financial expectations such as expectations for hiring, surgeon training and adoption, active surgeons, new products, clinical trial enrollment and reimbursement decisions and are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission.